KR102421423B1 - 키토산을 포함하는 열-살균 제형 및 이의 제조방법 - Google Patents

키토산을 포함하는 열-살균 제형 및 이의 제조방법 Download PDF

Info

Publication number
KR102421423B1
KR102421423B1 KR1020177009821A KR20177009821A KR102421423B1 KR 102421423 B1 KR102421423 B1 KR 102421423B1 KR 1020177009821 A KR1020177009821 A KR 1020177009821A KR 20177009821 A KR20177009821 A KR 20177009821A KR 102421423 B1 KR102421423 B1 KR 102421423B1
Authority
KR
South Korea
Prior art keywords
chitosan
composition
heat
acid
sterilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177009821A
Other languages
English (en)
Korean (ko)
Other versions
KR20170076659A (ko
Inventor
레일라 욜란다 보시
알레산드로 디 나폴리
Original Assignee
라보라뚜와르 메디동 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라뚜와르 메디동 에스.에이. filed Critical 라보라뚜와르 메디동 에스.에이.
Publication of KR20170076659A publication Critical patent/KR20170076659A/ko
Application granted granted Critical
Publication of KR102421423B1 publication Critical patent/KR102421423B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/05—Alcohols; Metal alcoholates
    • C08K5/053—Polyhydroxylic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61L2/0023—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/12—Amylose; Amylopectin; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/10—Medicinal preparations other than biologicals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/10—Transparent films; Clear coatings; Transparent materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/54—Aqueous solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177009821A 2014-10-29 2015-10-28 키토산을 포함하는 열-살균 제형 및 이의 제조방법 Active KR102421423B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/073246 WO2016066195A1 (en) 2014-10-29 2014-10-29 Heat-sterilized formulation comprising chitosan and process of preparation thereof
EPPCT/EP2014/073246 2014-10-29
PCT/IB2015/058300 WO2016067210A1 (en) 2014-10-29 2015-10-28 Heat-sterilized formulation comprising chitosan and process of preparation thereof

Publications (2)

Publication Number Publication Date
KR20170076659A KR20170076659A (ko) 2017-07-04
KR102421423B1 true KR102421423B1 (ko) 2022-07-15

Family

ID=51842529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009821A Active KR102421423B1 (ko) 2014-10-29 2015-10-28 키토산을 포함하는 열-살균 제형 및 이의 제조방법

Country Status (17)

Country Link
US (1) US10493155B2 (cg-RX-API-DMAC10.html)
EP (1) EP3212166B1 (cg-RX-API-DMAC10.html)
JP (1) JP6814133B2 (cg-RX-API-DMAC10.html)
KR (1) KR102421423B1 (cg-RX-API-DMAC10.html)
CN (1) CN107075174B (cg-RX-API-DMAC10.html)
CA (1) CA2965447C (cg-RX-API-DMAC10.html)
CO (1) CO2017003840A2 (cg-RX-API-DMAC10.html)
DK (1) DK3212166T3 (cg-RX-API-DMAC10.html)
ES (1) ES2857273T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201995T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053432T2 (cg-RX-API-DMAC10.html)
MX (1) MX383011B (cg-RX-API-DMAC10.html)
PT (1) PT3212166T (cg-RX-API-DMAC10.html)
RS (1) RS61214B1 (cg-RX-API-DMAC10.html)
RU (1) RU2712271C2 (cg-RX-API-DMAC10.html)
SI (1) SI3212166T1 (cg-RX-API-DMAC10.html)
WO (2) WO2016066195A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof
JP7723603B2 (ja) 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
CN114667103A (zh) 2019-11-04 2022-06-24 柯惠有限合伙公司 用于治疗颅内动脉瘤的装置、系统和方法
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
JP7453036B2 (ja) * 2020-03-30 2024-03-19 株式会社ナリス化粧品 皮膚外用剤
CN114652866A (zh) * 2020-12-23 2022-06-24 上海其胜生物制剂有限公司 一种羧甲基几丁质溶液的湿热灭菌方法
WO2022198208A1 (en) 2021-03-16 2022-09-22 Covidien Lp Injectable biopolymer compositions and associated systems and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007139A2 (en) * 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
WO2000030609A1 (en) 1998-11-20 2000-06-02 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
JPS6462302A (en) * 1987-09-01 1989-03-08 Nippon Suisan Kaisha Ltd Water-soluble chitosan salt and production thereof
JPH06107551A (ja) * 1992-09-30 1994-04-19 Hisamitsu Pharmaceut Co Inc 関節症治療剤
JPH07118304A (ja) * 1993-10-27 1995-05-09 Asahi Glass Co Ltd キトサン水溶液
US5420197A (en) * 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
JP5116129B2 (ja) * 2000-09-01 2013-01-09 日本水産株式会社 中性付近のキトサン水溶液の製造法
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
CA2501820C (en) * 2002-10-08 2009-12-15 Ricom Corporation Chitosan-containing polysaccharide, method for preparing the same and use thereof
DK1978925T3 (da) * 2005-12-23 2009-12-14 Medidom Lab Termohærdende neutraliseret chitosansammensætning, der danner en hydrogel, lyofilisat og fremgangsmåder til fremstilling deraf
US9034348B2 (en) * 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007139A2 (en) * 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
WO2000030609A1 (en) 1998-11-20 2000-06-02 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan

Also Published As

Publication number Publication date
MX383011B (es) 2025-03-13
WO2016066195A1 (en) 2016-05-06
CN107075174A (zh) 2017-08-18
CA2965447C (en) 2022-05-31
BR112017008353A2 (pt) 2017-12-19
ES2857273T3 (es) 2021-09-28
RU2017118261A (ru) 2018-11-29
SI3212166T1 (sl) 2021-01-29
HRP20201995T1 (hr) 2021-02-05
WO2016067210A1 (en) 2016-05-06
KR20170076659A (ko) 2017-07-04
RU2017118261A3 (cg-RX-API-DMAC10.html) 2019-04-25
US10493155B2 (en) 2019-12-03
US20170312364A1 (en) 2017-11-02
HUE053432T2 (hu) 2021-07-28
PT3212166T (pt) 2021-02-09
EP3212166B1 (en) 2020-12-02
JP2017533186A (ja) 2017-11-09
EP3212166A1 (en) 2017-09-06
CN107075174B (zh) 2021-03-30
DK3212166T3 (da) 2021-02-22
RS61214B1 (sr) 2021-01-29
CO2017003840A2 (es) 2017-04-28
RU2712271C2 (ru) 2020-01-28
CA2965447A1 (en) 2016-05-06
MX2017004760A (es) 2017-07-26
JP6814133B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
US10493155B2 (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
CA3002384C (en) Pharmaceutical formulations that form gel in situ
AU2016262185B2 (en) Aqueous suspension agent comprising glucocorticosteroid nanoparticles
TW201521785A (zh) 含有巨環內酯系抗菌劑之奈米微粒子之水性懸濁液劑
Lu et al. Enhanced antibacterial and antibiofilm activities of quaternized ultra-highly deacetylated chitosan against multidrug-resistant bacteria
EP1128809B1 (en) Aqueous ophthalmic formulations comprising chitosan
KR101341647B1 (ko) 베타-글루칸을 포함하는 각결막염 치료용 점안제 조성물
HK1238537B (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
HK1238537A1 (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
Alaimo et al. Chitosan-based nanosuspensions for ocular diagnosis and therapy
BR112017008353B1 (pt) Formulação termoesterilizada compreendendo quitosana e processo de preparação da mesma
EP4667000A1 (en) Hyperosmolar ophthalmic composition comprising carboxymethyl chitosan
Islam et al. Chitosan-based gels for ocular drug delivery
IL324271A (en) Method of treating operative complications of cataract surgery
Elçin Panomycocin-incorporated chitosan-tpp nanoparticles: preparation, characterization and in vitro determination of antifungal activity against human dermatophytes
HK1248100B (en) Pharmaceutical formulations that form gel in situ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5